Welcome to our dedicated page for Optimi Health SEC filings (Ticker: OPTHF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Optimi Health Corp. (OPTHF) SEC filings page on Stock Titan is intended to organize the company’s U.S. regulatory disclosures alongside its broader public reporting. While recent company information has been communicated primarily through news releases and Canadian regulatory channels, any future U.S. filings, such as registration statements or periodic reports, will appear here once available through EDGAR.
Optimi has publicly announced the filing of a registration statement on Form F-1 with the U.S. Securities and Exchange Commission in connection with a proposed initial public offering of its common shares in the United States and an application to list on the Nasdaq Capital Market under the symbol "OPTH." When effective filings of this type, or any subsequent amendments, become available, they can provide detail on Optimi’s business description, risk factors, use of proceeds, and share structure.
On this page, Stock Titan will surface key SEC documents relevant to Optimi’s activities as a Health Canada-licensed, GMP-compliant manufacturer of natural psilocybin and MDMA. These may include registration statements, annual and interim reports if the company becomes a reporting issuer in the U.S., and any other forms that outline its operations in pharmaceutical preparation manufacturing and controlled substance handling.
AI-powered tools on Stock Titan are designed to help interpret lengthy filings by highlighting important sections, summarizing complex disclosures, and drawing attention to items that matter to investors, such as business overviews and risk discussions. As Optimi’s U.S. regulatory footprint develops, this page will serve as a central location to review its SEC submissions alongside AI-generated insights, complementing the company’s Canadian and international regulatory disclosures.
Optimi Health Corp. is conducting an initial public offering of 2,500,000 common shares in the United States, and is registering related underwriter warrants to purchase up to 143,750 common shares plus the shares issuable on their exercise. The prospectus assumes an initial public offering price between US$6.00 and US$8.00 per share and reflects an approved 1-for-30 reverse share split to meet Nasdaq listing requirements. The company has applied to list on Nasdaq under the symbol OPTH and currently trades on the CSE (OPTI), FSE (8BN) and OTCQX (OPTHF). Financials show revenue and recurring losses, with a December 31, 2025 cash/asset snapshot and accumulated deficit disclosed; the company states existing cash, term loan funding and this offering are expected to fund operations for the next 12 months.
Optimi Health Corp. is registering an initial public offering in the United States of 2,142,857 common shares.
The registration also covers underwriting arrangements including warrants to purchase up to 123,214 common shares and an equal number of shares issuable upon exercise of those warrants. The prospectus assumes an initial public offering price between US$6.00 and US$8.00 per share. Completion of the offering is conditioned on approval for listing on the Nasdaq Capital Market. The company has approved a 1-for-30 reverse share split to be effected prior to effectiveness; all share data in the prospectus reflect that split.
Optimi Health Corp. has filed an amended F-1 for an initial public offering of its common shares in the United States, with the deal contingent on approval to list on the Nasdaq Capital Market under the symbol “OPTH”.
The Canadian company is a GMP-compliant pharmaceutical manufacturer focused on MDMA and botanical psilocybin, supplying regulated psychedelic medicines to markets such as Australia and Canada under strict Health Canada licensing. Optimi plans a reverse share split immediately before uplisting to meet Nasdaq’s minimum share price requirements.
Optimi reports modest revenue and continuing losses, including C$426,301 in revenue and a C$3,712,031 loss for the year ended September 30, 2025, and discloses substantial doubt about its ability to continue as a going concern without additional capital. Extensive risk factors highlight heavy regulatory dependence, controlled-substance compliance, evolving global rules, competition in a nascent psychedelics industry and the need for future financing to support expansion, including any eventual U.S. market entry.